| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/11/2013 | EP2671574A1 Use of vitamin K to decrease allograft failure and patient mortality after organ transplantation |
| 12/11/2013 | EP2671572A1 Patch and patch preparation |
| 12/11/2013 | EP2671565A1 External preparation for skin |
| 12/11/2013 | EP2670780A1 Cellulose-based nanoparticles for drug delivery |
| 12/11/2013 | EP2670765A1 C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity |
| 12/11/2013 | EP2670764A1 C-28 amines of c-3 modified betulinic acid derivatives as hiv maturation inhibitors |
| 12/11/2013 | EP2670756A1 Process for making everolimus |
| 12/11/2013 | EP2670754A1 (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases |
| 12/11/2013 | EP2670753A1 Novel heterocyclic derivatives |
| 12/11/2013 | EP2670752A1 Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels |
| 12/11/2013 | EP2670751A1 Methods of making hiv attachment inhibitor prodrug compound and intermediates |
| 12/11/2013 | EP2670750A1 Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase |
| 12/11/2013 | EP2670749A1 New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| 12/11/2013 | EP2670748A2 7-azaindole derivatives |
| 12/11/2013 | EP2670746A1 Bicyclic heteroaryl compounds as gpr119 receptor agonists |
| 12/11/2013 | EP2670745A1 Spiro aminic compounds with nk1 antagonist activity |
| 12/11/2013 | EP2670744A1 Pyrrole derivatives used as modulators of alpha7 nachr |
| 12/11/2013 | EP2670740A1 Amidobenzothiazoles and process for the preparation thereof |
| 12/11/2013 | EP2670739A1 Benzothiazole hybrids useful as anticancer agents and process for the preparation thereof |
| 12/11/2013 | EP2670738A2 1,4 oxazines as bace1 and/or bace2 inhibitors |
| 12/11/2013 | EP2670737A1 Method of preparation of metaxalone |
| 12/11/2013 | EP2670736A1 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof |
| 12/11/2013 | EP2670734A1 Novel ether linked compounds and improved treatments for cardiac and cardiovascular disease |
| 12/11/2013 | EP2670733A2 Hdac inhibitors and therapeutic methods using the same |
| 12/11/2013 | EP2670731A1 Positive allosteric modulators of the alpha 7 nicotinic acetylcholine receptor and uses thereof. |
| 12/11/2013 | EP2670486A1 Treatment for lipodystrophy |
| 12/11/2013 | EP2670439A1 Active principle for mitigating undesired medical conditions |
| 12/11/2013 | EP2670427A1 Prevention of hypoglycaemia in diabetes mellitus type 2 patients |
| 12/11/2013 | EP2670417A1 Methods and compositions for treating bacterial infections with iron chelators |
| 12/11/2013 | EP2670412A1 Treatment of bone marrow edema (oedema) with polysulfated polysaccharides |
| 12/11/2013 | EP2670411A1 Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf) |
| 12/11/2013 | EP2670410A1 Antimicrobial 4-oxoquinolizines |
| 12/11/2013 | EP2670409A1 Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder |
| 12/11/2013 | EP2670408A1 (5s,8s)-3-(4'-chlor-3'-fluor-4-methlybiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for treatment |
| 12/11/2013 | EP2670407A2 Treatment of bacterial infections |
| 12/11/2013 | EP2670406A1 Combination therapy with interferon and andrographolides for multiple sclerosis |
| 12/11/2013 | EP2670405A1 Combinations comprising macitentan for the treatment of glioblastoma multiforme |
| 12/11/2013 | EP2670404A1 Sirtuin modulators as virus production modulators |
| 12/11/2013 | EP2670403A1 Methods for treating brain injury |
| 12/11/2013 | EP2670402A1 Isolated compounds from turmeric oil and methods of use |
| 12/11/2013 | EP2670401A1 Methods of using alk inhibitors |
| 12/11/2013 | EP2670400A1 Pharmaceutical composition comprising opioid agonist and sequestered antagonist |
| 12/11/2013 | EP2670398A1 Implantable device for controlled release of low solubility drug |
| 12/11/2013 | EP2670396A1 Pharmaceutical compositions of cytidine analogs and methods of use thereof |
| 12/11/2013 | EP2670395A1 Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases |
| 12/11/2013 | EP2670390A2 Compostions and methods for treating chronic inflammation and inflammatory diseases |
| 12/11/2013 | EP2670389A1 Compositions and methods for treating cardiovascular diseases |
| 12/11/2013 | EP2670388A2 Method of making ophthalmic devices and components thereof from hydrophobic acrylic (ha) polymers with reduced or eliminated glistenings |
| 12/11/2013 | EP2670387A1 Oral controlled release pharmaceutical compositions of bepotastine |
| 12/11/2013 | EP2670245A1 Alpha-ketoheterocycles and methods of making and using |
| 12/11/2013 | EP2670244A2 Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
| 12/11/2013 | EP2670243A1 Compositions and methods for treatment of glaucoma |
| 12/11/2013 | EP2670242A1 Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| 12/11/2013 | EP2328414B1 Substituted triazolo-pyridazine derivatives |
| 12/11/2013 | CN203329063U Disintegration-structure DHA (docosahexenoic acid) soft capsule |
| 12/11/2013 | CN1956952B Histamine H3 receptor agents, preparation and therapeutic uses |
| 12/11/2013 | CN103443276A Molecular targets for healing or treating wounds |
| 12/11/2013 | CN103443114A FGF receptor-activating 3-O-alkyl oligosaccharides, preparation thereof and therapeutic use thereof |
| 12/11/2013 | CN103443107A Thiazolopyrimidine compounds |
| 12/11/2013 | CN103443106A Novel octahydrothienoquinoline derivatives, pharmaceutical compositions comprising the derivatives and uses of the pharmaceutical compositions |
| 12/11/2013 | CN103443105A Chroman-spirocyclic piperidine amides as modulators of ion channels |
| 12/11/2013 | CN103443103A Novel Fusarisetin compounds, and use thereof |
| 12/11/2013 | CN103443102A Bicyclic carboxamide inhibitors of kinases |
| 12/11/2013 | CN103443100A Substituted 6-midazopyrazines for use as mps-1 and TKK inhibitors in the treatment of hyperproliferative disorders |
| 12/11/2013 | CN103443099A Compositions and methods for modulating FXR |
| 12/11/2013 | CN103443098A Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof |
| 12/11/2013 | CN103443097A Fused dihydrofurans as GPR119 modulators for the treatment of diabetes, obesity and related disorders |
| 12/11/2013 | CN103443096A Pyrimidine gyrase and topoisomerase iv inhibitors |
| 12/11/2013 | CN103443094A Pyrazole derivative |
| 12/11/2013 | CN103443093A Novel compounds as histamine H3 receptor ligands |
| 12/11/2013 | CN103443092A Pyrrole derivatives used as modulators of alpha7 nachr |
| 12/11/2013 | CN103443083A Cancer targeting using carbonic anhydrase isoform IX inhibitors |
| 12/11/2013 | CN103443082A Prodrugs of LXR modulating imidazole derivatives |
| 12/11/2013 | CN103443080A Sulfonamide compounds having TRPM8 antagonistic activity |
| 12/11/2013 | CN103443079A Fluoro-pyridinone derivatives useful as antibacterial agents |
| 12/11/2013 | CN103443077A Trpm8受体拮抗剂 Trpm8 receptor antagonist |
| 12/11/2013 | CN103443076A Indol-2-one derivatives disubstituted in the 3-osition, preparation thereof and therapeutic use thereof |
| 12/11/2013 | CN103443075A Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease |
| 12/11/2013 | CN103443066A Ingenol-3-acylates I |
| 12/11/2013 | CN103442766A A 5-HT4 receptor agonist as a prokinetic agent |
| 12/11/2013 | CN103442735A Active principle for mitigating undesired medical conditions in technical field |
| 12/11/2013 | CN103442723A Systems and methods for treatment of allergies and other indications |
| 12/11/2013 | CN103442722A COX-2 inhibitors and related compounds, and systems and methods for delivery thereof |
| 12/11/2013 | CN103442721A Aqueous solution containing hyaluronic acid or salt thereof |
| 12/11/2013 | CN103442720A Aqueous solution containing hyaluronic acid or salt thereof |
| 12/11/2013 | CN103442719A Aqueous solution containing hyaluronic acid or salt thereof |
| 12/11/2013 | CN103442718A Aqueous solution containing hyaluronic acid or salt thereof |
| 12/11/2013 | CN103442717A Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases |
| 12/11/2013 | CN103442716A Composition usable in the treatment of cellular degeneration |
| 12/11/2013 | CN103442715A A pharmaceutical composition comprising an HDAC inhibitor and a steroid and the use thereof. |
| 12/11/2013 | CN103442714A Compounds, compositions and methods useful for cholesterol mobilisation |
| 12/11/2013 | CN103442713A Pharmaceutical formulation for topical administration comprising B220 |
| 12/11/2013 | CN103442712A Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
| 12/11/2013 | CN103442711A Treatment of cognitive dysfunction in schizophrenia |
| 12/11/2013 | CN103442710A Combination of checkpoint kinase 1 inhibitors and WEE1 kinase inhibitors |
| 12/11/2013 | CN103442708A Therapeutic treatment |
| 12/11/2013 | CN103442707A Gemcabene and derivatives for treating pancreatitis |
| 12/11/2013 | CN103442706A Thiol-containing compounds for the removal of elements from tissues and formulations therefor |
| 12/11/2013 | CN103442705A Combination of syrosingopine and mitochondrial inhibitors for the treatment of cancer and immunosuppression |
| 12/11/2013 | CN103442704A Cystamine analogues for the treatment of parkinson's disease |